The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER?

Hiten D. Patel, Maneka Puligandla, Brian M. Shuch, Bradley C. Leibovich, Anil Kapoor, Viraj A. Master, Charles G. Drake, Daniel Y.C. Heng, Primo N. Lara, Toni K. Choueiri, Deborah Maskens, Eric A. Singer, Scott E. Eggener, Robert S. Svatek, Walter M. Stadler, Suzanne Cole, Sabina Signoretti, Rajan T. Gupta, Marc Dror Michaelson, David F. McDermottDavid Cella, Lynne I. Wagner, Naomi B. Haas, Michael A. Carducci, Lauren C. Harshman, Mohamad E. Allaf

Producción científica: Articlerevisión exhaustiva

29 Citas (Scopus)

Resumen

While many patients with early stage kidney cancer can be cured by removal of the tumor and kidney ('nephrectomy'), upward of 40% of patients can recur due to microscopic spread of the cancer prior to surgery. Adding anticancer drugs that are effective in the metastatic setting to surgery has potential to eliminate the microscopic disease and increase cure rates. The PROSPER renal cell carcinoma study is testing whether adding nivolumab, a drug that engages the immune system to better recognize, fight and eliminate the cancer, will improve disease control over surgery alone. Nivolumab will be given before and after surgery to see if it reduces the chance of the disease returning and decreases death from kidney cancer compared with patients receiving surgery only.

Idioma originalEnglish (US)
Páginas (desde-hasta)1683-1695
Número de páginas13
PublicaciónFuture Oncology
Volumen15
N.º15
DOI
EstadoPublished - may 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER?'. En conjunto forman una huella única.

Citar esto